Perimenopause: Weight, Gut Health & Joint Pain
Weight gain, belly fat, bloating, digestive issues, joint pain, and muscle loss are common but often overlooked symptoms of perimenopause and hormonal changes in women. As estrogen and progesterone levels fluctuate, women may experience slower metabolism, changes in body composition, increased abdominal fat, difficulty losing weight, constipation, food sensitivities, joint stiffness, and unexplained shoulder pain, including a condition known as frozen shoulder (adhesive capsulitis). These changes can affect energy levels, mobility, digestive health, and overall quality of life, even when diet and exercise habits haven’t changed.
We take a comprehensive, individualized approach to perimenopause weight management, metabolic health, gut health, and joint pain evaluation. Our evidence-based strategies include strength training, personalized nutrition, body composition testing, resting metabolic rate testing, lifestyle modifications, and medical weight management, including GLP-1 medications when clinically appropriate. We also evaluate digestive concerns, hormonal changes, and musculoskeletal symptoms to identify potential underlying causes and appropriate treatment options. Whether you’re struggling with stubborn perimenopause belly fat, unexplained weight gain, persistent bloating, or joint stiffness, our goal is to help you better understand your changing body, preserve muscle mass, support long-term metabolic health, and feel stronger and healthier throughout the menopausal transition.
Weight and Body Composition Changes
Many people notice an increase in abdominal fat and a gradual loss of lean muscle mass during perimenopause, even without major changes to diet or activity. This reflects hormonal shifts and a naturally slowing metabolism as much as it does lifestyle, which is why the usual advice to simply “eat less, move more” often falls short.
Treatment options
- Strength training: Resistance exercise is the single most evidence-supported tool for preserving — and even rebuilding — lean muscle mass during this transition, which in turn supports a healthier metabolism.
- Nutrition adjustments: Adequate protein intake and calorie needs recalibrated to your actual metabolism — rather than guessed — make a meaningful difference; resting metabolic rate testing can take the guesswork out of this.
- Sleep and stress management: Poor sleep and chronically elevated stress both promote fat storage, particularly around the abdomen, so addressing them is a legitimate part of a weight-focused plan, not just a wellness afterthought.
- Medical weight management and peptide therapy: The hormonal shifts of perimenopause often bring changes in metabolism, body composition, and weight distribution — even without changes in diet or activity level. For some patients, peptide therapy is a useful addition to a treatment plan, though it’s an area where evidence and regulatory status vary widely by compound, and it’s worth understanding those differences.
GLP-1 receptor agonists. Semaglutide, tirzepatide, and liraglutide are FDA-approved for weight management in qualifying adults and are supported by extensive clinical trial evidence. For perimenopausal and menopausal women managing weight changes tied to hormonal shifts, these medications are often the most well-studied option and may be appropriate alongside other perimenopause care, depending on individual health history.
Other peptides marketed for “optimization.” Compounds such as growth-hormone secretagogues (e.g., CJC-1295, ipamorelin) and tissue-repair peptides (e.g., BPC-157) are increasingly marketed by wellness clinics for goals like muscle preservation, recovery, and anti-aging. It’s important to know that these carry meaningfully less clinical evidence than GLP-1 medications — most human data is limited, and much of the supporting research is preclinical. Their regulatory status has also been narrowing: the FDA has been reviewing and restricting which peptides compounding pharmacies may legally prepare, and access to several of these compounds has become more limited as of 2026.
We approach peptide therapy the way we approach every part of perimenopause treatment — grounded in the strength of the evidence for a given compound, your individual health profile, and current regulatory guidelines. We’ll always be transparent with you about which options are well-established medications versus which are newer or less-studied compounds, so you can make an informed decision.
Gut Health in Perimenopause
New bloating, erratic bowel habits, or a sudden sensitivity to foods that never used to bother you are common, under-discussed complaints during perimenopause — and a growing body of research suggests the gut itself is both affected by, and actively involved in, the hormonal changes of this transition.
The estrobolome: the gut's role in estrogen metabolism
A specific collection of gut bacteria, sometimes called the estrobolome, produces an enzyme (beta-glucuronidase) that helps determine how much estrogen the body reabsorbs versus clears through the digestive tract. In a well-balanced gut, this process helps keep circulating estrogen within a normal range. Research suggests the relationship runs in both directions: estrogen levels appear to shape which bacteria thrive in the gut, and in turn, the composition of those gut bacteria influences how much estrogen gets recirculated — meaning a disrupted gut community could, in theory, amplify the hormonal swings already happening during perimenopause.
What changes in the gut during this transition.
- Reduced microbial diversity. Multiple studies have found that gut microbiome diversity tends to decline as estrogen falls, with the postmenopausal gut community shifting to look more similar to a typical male gut microbiome than to a premenopausal woman’s. One study of over 2,300 participants found postmenopausal women had both lower gut diversity and lower levels of the estrogen-recycling enzyme than premenopausal women, and that these bacterial shifts tracked with cholesterol, waist circumference, and blood pressure — hinting at a connection between gut changes and the broader metabolic shifts many women notice in midlife.
- Slower gut motility. Declining estrogen and progesterone are thought to slow the rate at which food moves through the intestines, which can show up as constipation, a sense of incomplete emptying, and increased gas production from food sitting longer in the gut.
- A less resilient gut barrier. Estrogen and progesterone appear to help maintain the integrity of the gut lining; as they decline, some researchers describe a modest increase in gut permeability (sometimes colloquially called “leaky gut”), which may contribute to low-grade inflammation and new food sensitivities.
Common symptoms women report
An important evidence caveat
What may help
Based on general gut-health evidence and the mechanisms described above, several approaches are reasonable to discuss as part of a broader perimenopause plan:
- Fiber-rich foods to support gut motility and feed beneficial bacteria
- Fermented foods and, in some cases, probiotics, aimed at supporting microbial diversity, though strain-specific evidence in perimenopausal women specifically is still developing
- Adequate hydration, which supports regular bowel movements alongside fiber intake
- Regular physical activity, which independently supports gut motility
- Ruling out other causes of new digestive symptoms — including thyroid dysfunction, irritable bowel syndrome, and other gastrointestinal conditions — rather than attributing every gut symptom to hormones by default, since several of the conditions discussed elsewhere in this guide (thyroid changes, for instance) can also present with bowel changes.
Digestive changes are a legitimate, often overlooked part of the perimenopausal picture, tied to real shifts in hormone-gut interaction — but because the research is still maturing and gut symptoms can have many causes, persistent or severe digestive changes are worth evaluating directly with a provider rather than assumed to be hormonal by default.
Joint Aches
Treatment options
- Regular movement: Consistent, joint-friendly movement — walking, swimming, cycling, or strength training — maintains mobility and tends to reduce stiffness more effectively than rest.
- Anti-inflammatory strategies: Over-the-counter anti-inflammatory medication used as needed, along with an overall anti-inflammatory eating pattern, can help manage day-to-day discomfort.
- Hormone therapy: Some people notice a reduction in joint aches on hormone therapy, thought to relate to estrogen’s role in joint tissue, though this varies from person to person.
- Evaluation for other causes:Joint pain that comes with visible swelling, redness, or warmth — rather than plain stiffness — is worth having evaluated to rule out an inflammatory or autoimmune cause unrelated to perimenopause.
Frozen Shoulder: An Under-Recognized Perimenopausal Symptom
Shoulder pain and stiffness that develops gradually, without any clear injury, is another perimenopausal complaint that often gets overlooked — both by patients, who may assume it’s unrelated to hormones, and by clinicians, who may not think to ask about menopausal status during an orthopedic evaluation.
Frozen shoulder, medically known as adhesive capsulitis, is a condition in which the capsule surrounding the shoulder joint becomes inflamed and progressively thickened and fibrotic, causing pain and a significant loss of both active and passive range of motion — meaning the shoulder feels stuck even when someone else tries to move it for you, which helps distinguish it from other causes of shoulder pain. It affects an estimated 2 to 5% of the general population, with a clear peak in women between the ages of 40 and 60 — squarely overlapping with the perimenopausal and early postmenopausal years.
Why it's linked to perimenopause
Estrogen receptors are present directly in the tissue of the shoulder joint capsule, and estrogen appears to play a protective, anti-inflammatory role there. As estrogen declines, research suggests this can increase the expression of profibrotic signaling molecules (such as TGF-β and IL-6) that promote the synovial and capsular thickening characteristic of this condition — a plausible biological explanation for why the condition clusters so heavily around the menopause transition. Thyroid dysfunction and diabetes, both more common in this same age group, are also well-established risk factors and can compound the effect when they coexist with hormonal changes.
The typical course
Frozen shoulder generally progresses through three recognized stages: a painful “freezing” stage where motion becomes increasingly restricted, a “frozen” stage where pain may ease somewhat but stiffness remains pronounced, and a “thawing” stage where motion gradually returns. The full natural course, untreated, often spans one to three years, which is part of why early recognition and active treatment are valued — to shorten that timeline and reduce the pain and functional impact along the way.
Diagnosis
Frozen shoulder is primarily diagnosed clinically — based on the characteristic pattern of progressive pain and restricted motion in multiple directions — rather than through imaging. X-rays are typically normal and are mainly used to rule out other causes like arthritis; ultrasound can sometimes support the diagnosis and help distinguish it from related conditions like bursitis in the same area.
Treatment options
- Physical therapy is a cornerstone of treatment, using range-of-motion exercises, stretching, and modalities like heat or ice to maintain and gradually restore mobility — though therapy needs to be calibrated to the stage of the condition, since aggressive stretching too early in the painful phase can sometimes aggravate symptoms.
- NSAIDs help manage pain and inflammation, particularly in the early, more painful stage.
- Corticosteroid injections into the joint are commonly used, particularly in the earlier stages, to reduce inflammation and pain and allow more effective participation in physical therapy.
- Hydrodilatation (distension arthrography) involves injecting fluid into the joint capsule under imaging guidance to stretch and expand it, which can be effective for cases that don’t respond adequately to more conservative measures.
- Manipulation under anesthesia and arthroscopic capsular release are more involved interventions reserved for persistent, treatment-resistant cases, used to mechanically restore range of motion when other approaches haven’t worked.
What about hormone therapy?
This is an area of active research rather than established practice. Hormone therapy is not a validated or approved treatment for frozen shoulder itself, but observational research has found an association worth noting: one study found women not using hormone therapy were roughly twice as likely to develop frozen shoulder compared with those using it, suggesting a possible protective effect — though, as an observational finding, this shows association rather than proof that hormone therapy prevents or treats the condition. A randomized controlled trial currently underway is specifically testing whether hormone therapy, added to standard treatment, improves outcomes for peri- and postmenopausal women with frozen shoulder — reflecting that this question doesn’t yet have a definitive answer, even as the underlying estrogen-related mechanism described above is clinically plausible.
Any new, unexplained shoulder stiffness and pain during perimenopause is worth raising directly with a provider rather than dismissing as a simple strain or normal aging — early treatment can meaningfully shorten the course of this condition and reduce its impact, and recognizing the hormonal connection helps explain why it’s showing up now rather than suggesting something was done wrong.
Bone Health: A Benefit Many Women Don't Expect
Estrogen plays a critical role in maintaining bone density. Women reach peak bone density in the late 20s and start to lose bone around age 35. As estrogen levels decline during perimenopause, bone loss can accelerate — sometimes years before a woman even realizes she’s in the menopause transition. By the time bone loss shows up on a scan, a significant amount of density may already be gone.
Addressing hormonal changes early may help:
- Slow the rate of bone loss during the years when it accelerates most
- Reduce long-term fracture risk, particularly of the hip and spine
- Preserve mobility and independence later in life
For women with additional risk factors for osteoporosis — a family history, smoking, prior fractures, or a smaller body frame — early evaluation is especially valuable, since bone density lost during this window can be difficult to fully rebuild later.
Beyond Bones: Other Long-Term Benefits of Early Treatment
Cardiovascular health. Estrogen appears to offer some protective effects on blood vessels and cholesterol metabolism. Guidelines note that hormone therapy started within the recommended window has been associated with favorable cardiovascular outcomes in appropriately selected patients — though it is not prescribed specifically to prevent heart disease, and individual risk factors always guide the decision.
Cognitive and brain health. Researchers are actively studying the connection between the menopause transition and long-term brain health, given that women make up a disproportionate share of Alzheimer’s diagnoses. While this research is still evolving, it underscores why the perimenopausal years deserve real clinical attention.
Quality of daily life. Sleep, mood, energy, and cognitive clarity all tend to improve when vasomotor symptoms (hot flashes and night sweats) and hormonal fluctuations are properly managed — benefits that matter just as much as any long-term statistic.